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Diet-Related Metabolites Associated with Cognitive
Decline Revealed by Untargeted Metabolomics in a
Prospective Cohort
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Mireia Urpi-Sarda, Pierre Micheau, Melanie Petera, Delphine Centeno, Stephanie Durand,
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Boris P Hejblum, Catherine Helmer, Cristina Andres-Lacueva, Sandrine Thuret,
Ce´cilia Samieri,* and Claudine Manach
Scope: Untargetedmetabolomicsmay reveal preventive targets in cognitive aging, includingwithin the foodmetabolome.
Methods and results: A case-control study nested in the prospective Three-City study includes participants aged 65
years and initially free of dementia. A total of 209 cases of cognitive decline and 209 controls (matched for age, gen-
der, education) with slower cognitive decline over up to 12 years are contrasted. Using untargeted metabolomics and
bootstrap-enhanced penalized regression, a baseline serum signature of 22 metabolites associated with subsequent
cognitive decline is identified. The signature includes three coffee metabolites, a biomarker of citrus intake, a cocoa
metabolite, two metabolites putatively derived from fish and wine, three medium-chain acylcarnitines, glycodeoxycholic
acid, lysoPC(18:3), trimethyllysine, glucose, cortisol, creatinine, and arginine. Adding the 22 metabolites to a reference
predictive model for cognitive decline (conditioned on age, gender, education and including ApoE-ε4, diabetes, BMI,
and number of medications) substantially increases the predictive performance: cross-validated Area Under the Receiver
Operating Curve = 75% [95% CI 70–80%] compared to 62% [95% CI 56–67%].
Conclusions: The untargeted metabolomics study supports a protective role of specific foods (e.g., coffee, cocoa, fish)
and various alterations in the endogenous metabolism responsive to diet in cognitive aging.
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1. Introduction
Cognitive aging is a major public health concern worldwide.
Dementia and its main form Alzheimer’s disease (AD) are
leading causes of accelerated cognitive decline (CD), however
are lacking etiological treatment. As pathological processes are
thought to evolve over years before CD becomes apparent,
early prevention through diet management may be of criti-
cal importance.[1,2] Various plant-based healthy dietary patterns
have been related to a lower risk of dementia and CD;[3] yet,
only a few nutritional bioactives (e.g., long-chain omega-3 fatty
acids, vitamins, carotenoids, and polyphenols)[4] have been linked
to cognitive aging, and there is currently no consensus on a
gold-standard nutrition-based preventive strategy against cog-
nitive aging and dementia. With habitual diet providing up
to 25 000 compounds and additional thousands of host- and
gut microbiota-derived metabolites,[5] most interesting nutri-
tional compounds that may promote brain health likely remain
undiscovered.
Metabolomics may enable the identification of new pathways
and preventive targets in cognitive aging and dementia, particu-
larly within the food metabolome, that is, the part of the human
metabolome derived directly from food digestion. Metabolomics
provides a global picture of individuals’ biological status, as
it simultaneously measures a wide profile of metabolites in
biofluids, including diet-derived metabolites and endogenous
metabolites modulated by dietary intake.[6] Metabolomics has
the potential to capture the complexity of dietary exposures and
their impact on metabolism, taking into account inter-individual
variability.[5]
Epidemiological studies investigating metabolic changes in
dementia have only recently emerged, identifying new biomark-
ers of diagnosis and prognosis.[7–10] However, most of these
studies used a targeted metabolomics approach (i.e., assess-
ing a list of known metabolites, generally from the endoge-
nous metabolome),[9,10] thereby missing potential new metabo-
lites from the food metabolome. Moreover, these studies were
cross-sectional or used a short-term prospective design where
variations in the metabolome may reflect underlying diseases.
Lastly, very few studies have investigated the trajectory of cog-
nitive aging from a long-term perspective, which may be a more
powerful approach to capture predictors of both early (preclini-
cal) dementia stages and normal cognitive aging.
We therefore applied untargetedmetabolomics analysis on the
serum of participants from a large, well-established cohort on de-
mentia, who were initially free of dementia at the time of blood
draw (baseline) and provided repeated measures of cognition
over 12 years, to identify an early serummetabolomics signature
of subsequent CD.
Dr. S. Thuret
Department of Basic and Clinical Neuroscience
Maurice Wohl Neuroscience Institute
Institute of Psychiatry, Psychology and Neuroscience, King’s College
London
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2. Experimental Section
2.1. Population
The Three-City (3C) study is a French population-based co-
hort on dementia initiated in 1999–2000, including 9294 non-
institutionalized older persons aged 65 years selected from
the electoral rolls of three cities (Bordeaux [n = 2104], Dijon
[n= 4931], andMontpellier [n= 2259]).[11] The Consultative Com-
mittee for the Protection of Persons participating in Biomedical
Research at Kremlin-Biceˆtre University Hospital (Paris, France)
approved the 3C study protocol and all participants provided
written consent. At enrollment, face-to-face interviews were con-
ducted to collect socio-demographic and lifestyle characteristics
(including a food frequency questionnaire (FFQ)), medical in-
formation, cognitive testing, blood pressure and anthropomet-
ric measurements, and fasting blood samples for constitution of
a biobank. Follow-up visits were performed every two to three
years, including in-person neuropsychological assessments car-
ried out by a trained psychologist. Clinical diagnosis of demen-
tia was established and validated by an independent committee
of neurologists, using the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition.[12]
2.2. Study Design
A case-control study nested within the 3C-Bordeaux cohort was
constructed to investigate the relationships between variations in
serummetabolome and subsequent CD. 1293 participants not di-
agnosed with dementia at baseline, with available serum samples
in the biobank and with at least one repeated cognitive evaluation
over 12 years, were retained for case-control sampling (Figure
S1, Supporting Information). Then, individual slopes of cogni-
tive change estimated by a linear mixed model were used. The
primary outcome was the change in a composite score of global
cognition defined as the average of Z-scores of five neuropsycho-
logical tests at each follow-up (Mini-Mental State Examination,
Benton Visual Retention Test, Isaac’s Set Test, Trail-Making Test
part A, Trail-Making Test part B; see Method S1, Supporting In-
formation, for details). Cases were defined as participants with
the worst slopes of CD and controls as those with CD below me-
dian value (i.e., >median slope). Finally, 209 cases with greater
CD were successfully matched (based on age at baseline, gender
and educational level) to 209 controls with slower CD, leading to
a total sample size of n = 418 subjects.
2.3. Covariates
At baseline, regularly consumed medications were recorded and
cardio-metabolic risk factors were assessed, including BMI (kg
m−²), diabetes (fasting glucose 7.2 mmol L−1 or specific med-
ication) and fasting plasma levels of glucose, cholesterol, and
triglycerides (measured by routine enzymatic methods). ApoE-
ε4 genotype was defined as carrying at least one ε4 allele vs ab-
sence of ε4 allele. Lifestyle factors included regular physical activ-
ity ([yes/no] defined as having either an intensive leisure activity
[e.g., swimming] 1 h/week or a moderate activity [e.g., walking
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or household] 1 h per day); smoking status; alcohol consump-
tion; regular consumption of main food/beverage groups. For
physical activity, data were missing in 17% of the samples and
a specific missing category was created. For all other covariates,
missing values were <2% of the samples and the reference cat-
egory was assigned to missing data (for categorical variables) or
the median value (for continuous variables).
2.4. Dietary Data
Dietary habits were primarily assessed using a brief FFQ ad-
ministered concomitantly to blood sampling at baseline, which
recorded the frequency of intakes of 10 broad food/beverages[13]
and the number of glasses/cups per day of alcohol, wine, coffee,
and tea. For foods of specific interest to the study and not ascer-
tained in this FFQ (e.g., juices) and for specific nutrients/food
compounds (e.g., polyphenols), a more comprehensive FFQ and
a 24-h dietary recall administered in a subsample from 3C Bor-
deaux in 2001–2002 (data available for 351 participants out of the
418 subjects of the case-control study; seeMethod S1, Supporting
Information, for details) was used.
2.5. Sample Preparation and Untargeted LCMS Metabolomics
A detailed description of LCMS data acquisition and processing
is outlined in Method S2, Supporting Information. Briefly, fast-
ing baseline serum samples were de-proteinized with acidified
methanol. Metabolic profiles were acquired on a 22-min elution
gradient on an U300 UHPLC system (Thermo Scientific) cou-
pled to a high resolution QTOF (Bruker Impact HD2) operating
in positive electrospray ionization mode, with a scan range from
50 to 1000m/z. Quality controls were injected every ten samples
to monitor stability of the analytical system and allow signal drift
and batch effect correction.
LCMS data was processed using Galaxy WorkFlow4Meta-
bolomics, an open access web-based platform (http://work
flow4metabolomics.org/). Parameters used for peak detection,
grouping, retention time correction, quality checks, and signal
drift correction are detailed in Table S1, Supporting Information.
Amatrix of 1136 ions characterized by a retention time,m/z, and
relative intensity was obtained and used for correlation analyses.
Ions annotated as adducts, isotopes, or fragments of the same
metabolite or with high analytical variability or too low intensity
according to predefined thresholds were discarded, leaving a ma-
trix of 301 ions for LASSO regression analysis.
2.6. Statistical Analyses
In primary analyses, least absolute shrinkage and selection op-
erator (LASSO) conditional logistic regression was used to select
a set of metabolites associated with the odds of developing CD
over 12 years in the case-control study (Method S3, Supporting
Information).[14] The model was conditioned on matching vari-
ables (age, gender, and education), and adjusted for BMI and to-
tal number of medications regularly consumed. As LASSO re-
gression may lead to unstable solutions, bootstrap resampling
was used to enhance the robustness of variable selection.[15]
LASSO-penalized conditional logistic regressions were repeated
on 1000 bootstrapped samples; the metabolites were ordered
by decreasing percentage of selection across bootstraps and fo-
cused on those selected in >40% of bootstraps to define a serum
metabolomics signature of CD.
Several additional analyses were conducted. First, an un-
penalized conditional logistic regression was ran to estimate
the unbiased multivariable adjusted odds ratio (OR) of each
selected metabolite for greater versus slower CD (confidence
intervals were not estimated as known to be biased in post-
selection inference).[16] Second, the predictive ability of the sig-
nature compared to a reference predictive model conditioned
on age, gender, and education (the matching variables) and in-
cluding: (i) covariates from the selection model (BMI and med-
ication use), and (ii) ApoE-ε4 genotype and diabetes, two ad-
ditional important predictors of CD, was assessed. The added
value of the signature was evaluated for prediction of CD by
comparing Area Under the Receiver Operating Characteristic
Curves[17] between the reference predictive model and a model
additionally including the metabolomics signature. Area Un-
der the Curves (AUC) were computed using a leave-pair-out-
cross-validation and confidence intervals were obtained from
1000 bootstraps.
Moreover, several supplementary analyses were conducted to
assist in metabolite identification and interpretation of findings.
Pearson correlations of the 22 metabolites were estimated from
the signature with food/nutrient intakes assessed by the brief
baseline FFQ or the comprehensive FFQ and 24-h dietary re-
call collected two years later (Method S1, Supporting Informa-
tion). These analyses were exploratory as they were based on
subsamples with relevant dietary data available. Pearson corre-
lations between intakes of coffee and hydroxycinnamates and
the intensities of all ions (n = 1136) of metabolomic profiles
were also estimated. Analyses were controlled for the False Dis-
covery Rate (FDR) using Benjamini–Hochberg procedure. Pear-
son correlations between ions of interest were also examined.
Statistical analyses were performed using the R software ver-
sion 3.3.2. Penalized and un-penalized conditional logistic re-
gressions were fitted as stratified discrete-time Cox proportional
hazards models using the penalized and survival R packages,
respectively.
2.7. Metabolite Identification
In untargeted metabolomics, the chemical identity of the de-
tected ions is a priori unknown. The multi-step identification
process is described in Method S2, Supporting Information.
Briefly, in-house and online databases were queried to obtain
hypotheses of identification based on accurate mass. Custom-
curated databases of known biomarkers of intake for specific
foods, endogenous compounds associated with cognition and
the Bordeaux 3C medication list were also used for drawing
hypotheses of high biological plausibility. MS/MS fragmenta-
tion analyses were performed on the Bruker QTOF and on an
ultra-high resolution spectrometer LTQOrbitrap (Velos, Thermo-
Scientific). Fragmentation spectra were compared to those avail-
able in databases or in the literature, or to in silico predicted
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fragmentation pathways generated with MassFrontier (Thermo-
Scientific). Formal identification (level 1, as described by Sum-
ner et al.)[18] was obtained by matching of masses, fragmentation
pattern, and retention time to an authentic standard. When stan-
dards were not available, putative identification was obtained by
comparison to analytical data reported in online databases or in
the literature (for a compound [level 2] or a class of compounds
[level 3]).
3. Results
The participants were 76 years old on average at baseline; 66%
were female and 29% had reached secondary school or over
(Table 1). Participants were followed for cognition for an average
8.5 years (SD= 2.6). All participants were initially free of demen-
tia at the time of blood sampling; among cases of CD, 51% devel-
oped dementia during follow-up, versus 3% in the control group
(results not shown in the tables). Average BMI, plasma choles-
terol, and triglycerides were similar between groups at baseline
(p  0.12). In contrast, compared to controls, cases with greater
CD consumed a higher number ofmedications, had higher blood
glucose and were more often diabetics, carried more often the
ApoE-ε4 allele and practiced less regularly exercise (all p < 0.02).
The frequency of consumption of main food groups were simi-
lar between groups except for chocolate that was more frequently
consumed among controls (p < 0.01). Differences in intakes of
more detailed food groups and nutrient/food compounds is pro-
vided in Table S2, Supporting Information.
3.1. Identification of a Set of Serum Metabolites Associated with
Subsequent Cognitive Decline
The bootstrap-enhanced LASSO procedure identified a set of 22
ions robustly associated with CD (Figure 1). The multivariate
ORs and identification of these ions are presented in Table 2. A
complete description of the analytical data (m/z values, retention
times, elementary composition and MS/MS fragments) and as-
sociated information supporting identification of the 22 metabo-
lites are given in Table S3, Supporting Information and Figure
S2, Supporting Information. The serummetabolomics signature
included food-derived metabolites (atractyligenin glucuronide,
proline betaine, caffeine, 3-carboxy-4-methyl-5-pentyl-2-furan-
propionic acid (CMPFP), cyclo(prolyl-valyl), cyclo(leucyl-
prolyl)), ten endogenous metabolites (myristoylcarnitine, gly-
codeoxycholic acid 3-glucuronide (GDCA), glucose, creatinine,
N-trimethyllysine, 1-linolenoyl-sn-glycero-3-phosphocholine
(lysoPC(18:3)), cortisol, undecanoylcarnitine/4,8 dimethyl-
nonanoylcarnitine, arginine, lauroylcarnitine) and six unidenti-
fied metabolites (Table 2).
Adding the 22 metabolite-signature to a reference predictive
model (conditioned on age, gender and education, and including
ApoE-ε4, diabetes, BMI and number of medications) increased
the predictive performance for cognitive decline from a cross-
validated AUC of 62% (95%CI 56–67%) to 75% (95%CI 70–80%)
(Figure 2).
Table 1. Baseline characteristics of cases of cognitive decline (n = 209)
and controls with slower cognitive decline (>median slope, n = 209) in a
case-control study matched for age, gender and education, nested within
the 3C Bordeaux cohort.
Cases Controls pa)
Sociodemographic characteristics
Age (years) 75.9 (4.5) 75.7 (4.2) –
Gender, female 66.0 66.0 –
Education, secondary school 28.7 28.7 –
Health indicators
Number of drugs consumed 4.9 (2.7) 4.1 (2.4) <0.01
BMI (kg m−²) 26.8 (4.4) 26.1 (3.6) 0.12
Plasma total cholesterol (mmol L−1) 5.8 (0.9) 5.8 (1.0) 0.98
Plasma triglycerides (mmol L−1) 1.4 (0.8) 1.3 (0.6) 0.23
Plasma glucose (mmol L−1) 5.4 (1.6) 5.1 (1.0) 0.015
Diabetes 13.2 5.7 0.02
ApoE-ε4 carrier 26.2 12.0 <0.01
Lifestyle characteristics
Regular Physical activity 27.8 38.3 <0.01
Smoking status 0.75
Never 67.5 65.1
Former 27.8 30.6
Current 9.1 4.3
Beverage intakes
Alcoholic beverages (glasses/week) 9.4 (10.5) 10.8 (13.2) 0.20
Wine (glasses/week) 8.4 (9.5) 9.3 (11.5) 0.35
Regular coffee consumption (daily) 75.1 78.9 0.37
Regular tea consumption (daily) 25.4 22.0 0.39
Food groups, regular intakes
Dairy products (daily) 94.7 93.3 0.53
Meat (4 times/week) 65.6 62.2 0.47
Fish (2 times/week) 54.1 56.0 0.68
Eggs (2 times/week) 40.7 43.5 0.55
Cereal (daily) 93.8 94.7 0.68
Raw fruit (daily) 82.8 83.7 0.80
Raw vegetables (daily) 44.0 52.2 0.11
Cooked fruit and vegetables (daily) 72.7 77.5 0.29
Legumes (1 time/week) 30.1 28.7 0.75
Chocolate (2 times/week) 38.8 52.4 <0.01
Values aremean (SD) or percentages of non-missing values. ApoE-ε4, allele ε4 for the
apolipoprotein E gene; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
BMI, body mass index; a)Estimated using conditional logistic regression.
3.1.1. Food-Derived Metabolites
The metabolites with the highest rate of selection (>75%, Fig-
ure 1) were food-derivedmetabolites. The first-ranked compound
(Table 2) was atractyligenin glucuronide (m/z 497.2383), a diter-
penoid metabolite previously reported as a robust biomarker of
coffee intake.[19] Atractyligenin glucuronide was associated with
a lower odds of CD (multivariable-adjusted OR = 0.72). Con-
sistently, cyclo(leucyl-prolyl) (m/z 211.1441, 15th-ranked in boot-
strap selection), another known biomarker of coffee intake,[19,20]
was inversely associated with CD (OR = 0.68). In contrast,
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Figure 1. Identification of a metabolomics signature of cognitive decline in the 3C Bordeaux cohort (n = 418). We applied LASSO-penalized conditional
logistic regression on 1000 bootstrap samples to identify the ions/metabolites robustly associated with the odds of cognitive decline in the case-control
study. Ions/metabolites are ranked by decreasing frequency of selection across bootstraps. Dark grey bars indicate metabolites selected on the initial
sample, and light grey bars those selected on bootstrapped samples only. We retained the 22 ions/metabolites selected in >40% of bootstraps (with
names highlighted in bold font). For each bootstrapped model, the optimal penalization was chosen by leave-pair-out cross-validation. Models were
conditioned on the matching variables (age, gender, and level of education) and adjusted for body mass index and the number of medications regularly
consumed. Ion/metabolites are defined with their mass-to-charge ratio (M) and retention time (T).
caffeine (m/z 195.0876, third-ranked) was unexpectedly associ-
ated with higher odds of CD (OR = 1.75).
The second-ranked metabolite was identified as proline be-
taine (m/z 144.1018), a biomarker of citrus intake[21] that was
found associated with increased odds of CD (OR = 1.56). Three
other food-derivedmetabolites of the signature were inversely as-
sociated with CD: i) a metabolite tentatively identified as CMPFP
(m/z 251.1278, fourth-ranked: OR = 0.74), a structural deriva-
tive of a reported fish biomarker, 3-carboxy-4-methyl-5-propyl-
2-furanopropionic acid (CMPF),[22] ii) an unknown metabolite
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Table 2.Multivariate associations between the 22 serum ions/metabolites
selected in the metabolomics signature and the odds of subsequent cog-
nitive decline, in the 3C Bordeaux cohort (n = 418).
Selection
rank
Ion Metabolite name Identification
level
OR
1 M497.2383 T10.11 Atractyligenin glucuronide 2 0.72
2 M144.1018 T0.96 Proline betaine 1 1.56
3 M195.0876 T8.09 Caffeine 1 1.75
4 M251.1278 T13.25 CMPFP 2 0.74
5 M129.0658 T0.90 – 4 1.49
6 M160.1331 T0.97 – 4 1.83
7 M271.2056 T12.99 – 4 0.69
8 M197.1284 T7.95 Cyclo(prolyl-valyl) 1 0.90
9 M372.3108 T13.12 Myristoylcarnitine 1 1.01
10 M626.3536 T11.69 GDCA 1 1.12
11 M383.1161 T0.87 Glucose 1 1.24
12 M114.0660 T0.88 Creatinine 1 1.41
13 M189.1597 T0.79 N-trimethyl-Lysine 1 1.09
14 M159.0276 T1.15 – 4 1.40
15 M211.1441 T8.78 Cyclo(leucyl-prolyl) 1 0.68
16 M287.6256 T14.09 LysoPC(18:3) 2 0.76
17 M363.2166 T10.80 Cortisol 1 0.74
18 M330.2639 T11.58 Undecanoylcarnitine/4,8
dimethylnonanoylcarnitine
3 0.83
19 M245.0768 T1.15 – 4 1.29
20 M256.6796 T14.27 – 4 0.85
21 M175.1189 T0.81 L-Arginine 1 1.29
22 M344.2795 T12.23 Lauroylcarnitine 1 1.32
Ions/metabolites are ordered by decreasing frequency of selection across bootstraps
and referred to by mass-to-charge-ratio (M) and retention time (T). Odds Ratios
(ORs) for cognitive decline were estimated using a conditional logistic regression
conditioned on matching variables (age, gender and educational level) and adjusted
for BMI and number of medications regularly consumed. ORs are for 1SD-increment
of metabolite intensity. Confidence intervals are not valid in post-selection inference
and hence were not estimated. Level of identification is assigned as: 1, identification
validated with standards; 2, putative identification by comparison with databases
or literature; 3, putative identification of a chemical class; 4, unknown. CMPFP,
3-carboxy-4-methyl-5-pentyl-2-furanpropionic acid; GDCA, glycodeoxycholic acid-3-
glucuronide; LysoPC(18:3), 1-linolenoyl-sn-glycero-3-phosphocholine.
(m/z 271.2056, seventh-ranked; OR = 0.69) possibly linked to
red wine intake (see below correlations with dietary intake), and
iii) cyclo(prolyl-valyl) (m/z 197.1284; eight-ranked; OR = 0.90), a
diketopiperazine reported in chocolate, and other fermented and
heated foods.[23]
3.1.2. Endogenous Metabolites
Three endogenous metabolites were associated with lower odds
of CD, including lysoPC(18:3) (m/z 287.6256; 16th-ranked;
OR = 0.76), cortisol (m/z 363.2166; 17th-ranked; OR = 0.74)
and a medium-chain acylcarnitine (undecanoylcarnitine or 4,8
dimethylnonanoylcarnitine, m/z 330.2639, 18th-ranked; OR =
0.83). In contrast, six of the endogenous metabolites were asso-
ciated with greater odds of CD, including GDCA (m/z 626.3536;
10th-ranked; OR = 1.12), glucose (m/z 383.1160; 11th-ranked;
OR = 1.24), creatinine (m/z 114.0660; 12th-ranked; OR = 1.41),
trimethyllysine (m/z 189.1597; 13th-ranked; OR = 1.09), L-
arginine (m/z 175.1189; 21st-ranked; OR = 1.29), and lauroyl-
carnitine (m/z 344.2795; 22nd-ranked; OR = 1.32). Myristoylcar-
nitine (m/z 372.3108; ninth-ranked; OR = 1.01) were less clearly
associated with CD.
Associations of the 22 metabolites to CD were generally un-
changed (or slightly strengthened) when further adjusting for
ApoE-ε4, diabetes and physical activity. Only the association of
glucose to greater CD was attenuated when adjusting for dia-
betes, as expected; and the association of myristoylcarnitine with
lower CD arose when further adjusting for ApoE-ε4 status and
physical activity (OR = 0.81).
Despite our efforts, six ions (m/z 129.0658, 160.1331,
271.2056, 159.0276, 245.0768, and 256.6796) remain unidenti-
fied. Their spectral data are provided in Figure S2, Supporting
Information.
3.2. Associations between the 22 Serum Metabolites of the
Signature and Food/Nutrient Intakes
In supplementary analyses, we examined the correlations be-
tween the 22 serum metabolites from the signature and
food/nutrient intakes recorded in the 3C cohort (see Figure
S3, Supporting Information, for heatmap of correlations). Two
metabolites, atractyligenin glucuronide, and cyclo(leucyl-prolyl),
were correlated with coffee intake (r = 0.39 and r = 0.37 re-
spectively) and hydroxycinnamates (r = 0.25, 0.36), while unex-
pectedly, caffeine was not (r = 0.15 and 0.14, p > 0.08). More-
over, caffeine was not significantly correlated with other dietary
sources of caffeine, including tea and chocolate (p > 0.13), while
soda drinks, a known source of caffeine, were not examined
as poorly consumed in this older population. To provide ad-
ditional insight on the relationship between coffee and CD in
our cohort, we analyzed the correlations between all ions of the
untargeted metabolomics profile (irrespective of the signature)
and the intakes of coffee and its major polyphenol class, hy-
droxycinnamates. Five ions/metabolites were significantly corre-
lated with coffee intake, including atractyligenin glucuronide and
cyclo(leucyl-prolyl) that had the strongest correlations (Figure S4,
Supporting Information). The ion (m/z 96.0444, 1.17 min, un-
known) showed high correlations with coffee intake (r = 0.39),
hydroxycinnamates (r = 0.26), atractyligenin glucuronide (r =
0.55), and cyclo(leucyl-prolyl) (r = 0.38). This unidentified ion
(Figure S2, Supporting Information ) was not in the signature
but had a univariate odds ratio for CD of 0.90 (for 1SD-increase
in intensity). Paraxanthine (m/z 181.0720, RT 7.44 min, level 1),
the major metabolite of caffeine, and trigonelline (m/z 138.0535,
RT 0.93 min, level 1), previously proposed as a biomarker of
coffee intake,[24] but also of legumes,[25] were modestly corre-
lated with coffee intake (r = 0.26 and r = 0.18) and showed
no association with CD (univariate OR for 1SD-increase = 0.98
and 1.03, respectively). In conclusion, atractyligenin glucuronide,
cyclo(leucyl-prolyl), and m/z 96.0444 were the best markers of
coffee intake and were all associated with a reduced risk of CD
while caffeine, paraxanthine, and trigonelline reflected coffee
intake much less accurately and were inconsistently associated
with CD.
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Figure 2. Cross-validated ROC curves for a reference predictive model for cognitive decline (light grey curve) and a model additionally including the
22 metabolite-signature (dark grey curve), the 3C Bordeaux cohort (n = 418). Areas Under the Curve (AUC) were estimated using conditional logistic
regressions conditioned on age at baseline, gender and level of education and adjusted for body mass index, number of medications, ApoE-ε4 geno-
type and diabetes. ROC curves and AUCs were estimated by leave-pair-out cross-validation; confidence intervals for AUC were computed from 1000
bootstraps.
Proline betaine was correlated with citrus juice intake
(r = 0.32, p < 0.001), total citrus (r = 0.27, p < 0.001), citrus-
specific flavanones (r = 0.28, p < 0.001), and vitamin C intake
(r = 0.20, p = 0.011) but not with citrus fruit intake (r = 0.13,
p = 0.34). CMPFP was not correlated with any food/nutrient
(Figure S3, Supporting Information). We found a positive corre-
lation between CMPFP and CMPF in our metabolomics profiles
(r = 0.37). Both compounds are gut microbial metabolites of fu-
ran fatty acids that are found in high amounts in marine fish.[26]
CMPF, however not CMPFP, was correlated with fish intake
(r = 0.27, p < 0.001, and r = −0.02, p = 0.93, respectively).
One unidentified compound (m/z 271.2056) correlated with
wine intake (r = 0.34), red wine intake (r = 0.25), caloric intake
(r = 0.19), polysaccharides (r = 0.21), alcohol (r = 0.27), and
major wine polyphenols including dihydroflavonols (r = 0.25),
proanthocyanidins (PACs, r = 0.19), stilbenes (r = 0.26), and lig-
nans (r = 0.24) (all p  0.02). Cyclo(prolyl-valyl) correlated with
chocolate intake (r = 0.22, p < 0.001), PACs (r = 0.20, p = 0.001),
themajor polyphenols of cocoa, and serum levels of theobromine
(r = 0.65, p < 0.001), a purine alkaloid primarily found in choco-
late in Western diets.[27] These data suggest that cyclo(prolyl-
valyl), known as an abundant diketopiperazine in roasted cocoa
beans,[28] may represent a new candidate biomarker of cocoa in-
take. This also suggests that chocolate consumption could be as-
sociated with slower CD in our study. Interestingly, theobromine
was correlated with chocolate intake (r = 0.20) and although not
selected in the 22 metabolite-signature, was found negatively as-
sociated to CD (univariate OR for 1SD-increase = 0.85).
4. Discussion
Using untargeted metabolomics, we identified in the serum
of older persons free of dementia, 22 metabolites associated
with subsequent CD over 12 years. Several metabolites were re-
lated to coffee intake including atractyligenin glucuronide and
cyclo(leucyl-prolyl), two biomarkers of coffee intake, that clearly
suggest a protective association of coffee consumption with CD
in this older population. There is biological and epidemiologi-
cal evidence supporting a protective role of coffee on neurolog-
ical function. Observational studies, including the 3C study,[29]
have reported associations between coffee intake and a lower risk
of age-related cognitive disorders, although prospective cohort
studies are still limited in number and have showed inconsis-
tent results.[30,31] Among the vast number of coffee compounds,
polyphenols (e.g., chlorogenic acids), diterpenes, trigonelline,
melanoidins, and caffeine may exert cell signaling, prebiotic,
antioxidant, anti-inflammatory, antihypertensive, hypoglycemic,
vasculoprotective, and neurostimulant activities.[32,33] Many of
these compounds could contribute to the neuroprotective ef-
fects of coffee including those bioactives with a short pharma-
cokinetic profile during the postprandial phase and hence not
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detected in the fasting serum samples in our study. Unexpect-
edly, we found an inconsistent association of serum caffeine with
greater odds of CD. A protective effect of caffeine on CD has been
suggested,[29–32] although the body of evidence is weak and cof-
fee effect may have been unduly attributed to caffeine. Many in-
vestigators used the number of cups of coffee consumed to as-
sess caffeine exposure. Yet, circulating levels of caffeine do not
depend only on the quantity ingested but are largely affected
by genetic polymorphisms (e.g., CYP1A2) and co-ingestion of
drugs (e.g., cardiovascular medications, estrogen replacement
therapy).[34] The possible negative effect of caffeine in some
population subgroups deserves further investigation. It may be
linked to interactions with drugs or bioactive compounds, or to
genetic polymorphisms affecting caffeine bioactivity on specific
targets such as adenosine receptor A2.[34] Finally, our findings
support a protective effect of coffee, while caffeine was not the
major bioactive compound involved and may even have counter-
acted the beneficial activity of other coffee compounds in some
individuals. Future research with accurate measurement of all
coffee-derived metabolites in blood should provide a better un-
derstanding of components actually involved in coffee protective
effects.
Proline betaine, a well-validated biomarker of citrus
intake,[21,35] was another important food-derived metabolite
found associated with greater CD in this study. This observation
is in agreement with a smaller metabolomics study that iden-
tified proline betaine among the increased serum metabolites
in AD patients,[36] Yet, it contrasts with the reported beneficial
role of citrus fruit, which are good sources of antioxidant and
vasculoprotective nutrients (e.g., vitamin C and flavanones).[37,38]
Moreover, the consumption of citrus fruit has been related to
a lower risk of dementia.[39] However, these benefits may be
limited to fresh fruit or 100% fruit juices, since most commercial
juices contain added sugars and have a similar energy density
to soft drinks,[40] which adversely impact health.[41,42] In the
Framingham Heart Study, daily fruit juice intake was associated
with lower brain volume and poorer episodic memory.[42] In
our study, the correlation analyses suggest that proline betaine
mostly derived from juices.
Cyclo(prolyl-valyl) and theobromine, derivatives of cocoa prod-
ucts, showed lower odds of CD, which is in accordance with
previous observational results on chocolate intake and reduced
CD,[43] and with human intervention studies demonstrating that
the consumption of cocoa flavanols can improve hippocampal
vascular plasticity and reduce CD in healthy older persons.[44,45]
We also found a putative marker of fish intake, CMPFP, to be as-
sociated with lower odds of CD. There is a large epidemiological
literature linking fish consumption to lower CD[46] and although
CMPFP did not significantly correlate with fish intake in our
sample, CMPFP was found increased after consuming fish-rich
Mediterranean and Nordic diets in two untargetedmetabolomics
studies,[47,48] and was recently confirmed as a potential biomarker
of fish.[49] Moreover, we found an unidentified ion highly corre-
lated with (red) wine intake, to be associated with lower odds of
CD. Accordingly, in ameta-analysis, light-to-moderate alcohol in-
take, especially wine, was related to a lower risk of dementia.[50]
The signature included several endogenous metabolites pre-
viously reported to be dysregulated in metabolic syndrome or
early in the course of AD, for example, the three acylcarnitines
(myristoylcarnitine, undecanoylcarnitine/4,8 dimethylnonanoyl-
carnitine and lauroylcarnitine). Changes in plasma acylcarnitines
are indicators of incomplete fatty acid beta-oxidation in mito-
chondria and have been associated with overfeeding, high-fat
diets and metabolic syndrome.[51,52] In a rat model of cafeteria
diet-induced obesity, lauroylcarnitine was demonstrated to drive
the polarization of macrophages towards the pro-inflammatory
“M1” phenotype, potentially mediating the pro-inflammatory
response to an unbalanced diet.[52] Other studies reported vari-
ations of plasma medium-chain acylcarnitines in AD and pre-
clinical AD[53,54]; however, the species involved has so far been
inconsistent. A conjugated secondary bile acid (GDCA) and a
glycerophospholipid (lysoPC(18:3)) were also associated with CD
in our study. A disturbed cholesterol and lipid metabolism in the
brain has long been suspected in AD.[55] In particular, growing
evidence suggests a link between increased blood levels of spe-
cific bile acids, including GDCA, and AD.[7,56] Considering the
multiple roles of bile acids and their modulation by diet, exer-
cise, and gut microbiota, their comprehensive profiling in fu-
ture studies on CDwould certainly be informative. Another com-
pound of the signature, trimethyllysine (TML), may point toward
a putative role of the gut-brain axis in cognitive aging. TML is
released from proteins degraded in lysosomes and is a precur-
sor of carnitine. Interestingly, we observed a correlation (r =
0.44) between TML and the gut microbial metabolite of carni-
tine trimethylamine-N-oxide (TMAO), which has been linked to
cardiovascular diseases.[57] The effects of TML on health and ag-
ing are poorly documented, with the notable exception of a recent
untargeted metabolomics study reporting an association of TML
with increased risk of cardiovascular diseases.[58]
The findings regarding glucose and creatinine are in accor-
dance with previous literature,[59,60] with a strong relation be-
tween diabetes and a greater risk of dementia. With respect
to arginine, a few untargeted metabolomics studies reported
an increased serum concentration in cognitively impaired older
persons[8] and a lower plasma arginine was one of the most sig-
nificantmetabolic differences in older adults with superiormem-
ory performance compared to subjects with normal performance
or cognitive disorders.[61] The inverse association between higher
blood cortisol and slower CDwas less expected as excessive levels
of cortisol have been related with CD in older ages.[62–64] How-
ever, studies have not all been consistent and for example, our
findings are in accordance with a study reporting inverse associa-
tions between serum cortisol and cerebrospinal fluid biomarkers
of AD.[65]
Our study has major strengths, including a population-based
prospective design with repeated cognitive assessment over up
to 12 years, a rigorous case-control sampling inspired by inci-
dence density sampling (as recommended for nested case con-
trol studies), and the use of state-of-the art methods for both un-
targeted metabolomics and statistical modeling. However, some
limitations should be stressed. New findings from this discov-
ery study will require external validation. Only the accumulation
of high-quality metabolomics studies performed on independent
prospective cohorts with complementary analytical platformswill
allow developing a consolidated metabolic signature that can be
used universally to predict later CD. Although we controlled for
major possible confounders, we cannot rule out that other fac-
tors might have influenced the metabolic profiles, and residual
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confounding is still possible as in any epidemiological study.
Moreover, data collected by dietary surveys is prone to measure-
ment error, thus secondary analyses of correlations with food and
nutrient intakes should be interpreted with caution.
In conclusion, we discovered in non-demented participants
from a prospective cohort, a serum signature of subsequent CD
over 12 years, which increased the predictive ability beyond that
of standard predictors by 13%. The top metabolites were de-
rived from food/beverages and suggested a protective association
of coffee, cocoa, and fish with CD, while possible negative ef-
fects of citrus juice and caffeine deserves further investigation in
focused studies. The signature also revealed endogenousmetabo-
lites related to cardiometabolic health and known to be nega-
tively affected by an unbalanced diet. Whether replicated in in-
dependent cohorts, our results will provide new targets for pre-
ventive/therapeutic nutritional strategies against CD in older
persons.
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